What's Happening
Abbott Laboratories has agreed to pay $384.999 million to resolve U.S. government allegations that it manufactured powdered infant formula and nutritional products at facilities where manufacturing conditions created a substantial risk of contamination. The settlement covers products made at Abbott's Sturgis, Michigan, and Casa Grande, Arizona facilities between 2018 and 2022. (Reuters)
The U.S. Justice Department said Abbott allegedly failed to properly test products and did not alert regulators to positive contamination tests, while products were still being sold to programs funded by the U.S. Department of Agriculture (USDA) and Medicaid. Those programs subsidize infant formula for eligible low-income families. (Reuters)
The settlement resolves the government's civil claims, but it does not constitute a finding of liability, and Abbott did not admit wrongdoing. A related criminal investigation has also been closed. (Reuters)
What the Government Alleged
False Claims Act allegations center on non-compliant manufacturing and failure to notify
According to the settlement agreement, federal and state authorities alleged that from January 1, 2018, through December 31, 2022, Abbott did not manufacture powdered infant formula and nutritional products at the two facilities in compliance with applicable statutory, regulatory and contractual requirements. (Department of Justice)
The government specifically alleged that Abbott represented to the USDA, state agencies administering the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), and state Medicaid programs that its products complied with relevant requirements.
The claims were pursued under the False Claims Act, because government money was used to purchase some of the products involved. (Department of Justice)
Why WIC and Medicaid Matter
Public funding turns manufacturing quality into a healthcare-program integrity issue
This was not simply a dispute over manufacturing quality.
The government alleged that products made under the questioned conditions were ultimately purchased using public funds, including WIC and Medicaid money. That turns the matter into a healthcare-program integrity issue as well as a food-safety issue. (Department of Justice)
WIC provides nutritional assistance to eligible women, infants and children, while Medicaid funds healthcare for eligible populations. Infant formula is particularly important for families that depend on these programs to afford essential nutrition.
The Settlement Amount
Multi-million dollar breakdown across federal, state and whistleblower allocations
Abbott will pay a total of $384,999,040.12, plus applicable interest. (Department of Justice)
The agreement divides the payment among several parties:
- Federal Government: Abbott will pay approximately $348.7 million to the United States, plus interest, with about $174.35 million designated as restitution. (Department of Justice)
- Participating Medicaid States: Abbott will pay approximately $35.49 million to participating states, plus interest, including about $17.75 million in restitution. (Department of Justice)
- Massachusetts: A separate payment of approximately $806,884, plus interest, will go to Massachusetts under a supplemental WIC-related settlement. (Department of Justice)
- Whistleblowers: The settlement provides for $69 million to be distributed to the relators who brought the original qui tam lawsuit after the federal payment is received. (Department of Justice)
The 2022 Infant Formula Crisis
Contamination concerns and plant shutdowns triggered national supply disruptions
The settlement stems from events that became national news in 2022, when Abbott recalled infant formula after concerns about contamination with a potentially deadly bacterium.
Abbott shut down its Sturgis plant in Michigan after investigators found traces of the bacteria there. The closure and recall significantly reduced U.S. formula supply and worsened an already serious nationwide shortage caused in part by pandemic-related supply-chain disruptions. (Reuters)
The episode became one of the most significant U.S. food and infant-health supply disruptions of the period.
Because infant formula is an essential product for babies who depend on it for nutrition, the shutdown had consequences well beyond Abbott's own operations.
Abbott's Position
Company disputes allegations while maintaining safety focus
Abbott continues to dispute the government's allegations.
The company said that no unopened Abbott infant formula that had been distributed to consumers has ever tested positive for the bacterium referenced in the 2022 crisis. (Reuters)
Abbott also emphasized that product safety and quality remain priorities and said maintaining caregivers' trust is central to its business.
The settlement agreement itself explicitly states that Abbott denies the allegations and that the agreement is a compromise of disputed claims rather than an admission of facts or liability. (Department of Justice)
The Legal Case Behind the Settlement
Whistleblower action and state intervention expanded case significance
The underlying case began with a 2022 whistleblower lawsuit filed in federal court in Michigan.
The relators filed their original qui tam action in October 2022 under the False Claims Act. The case was later amended, and the United States partially intervened in 2025. Several states, including California, Maryland, Tennessee, Massachusetts, New York and Connecticut, also intervened in claims connected to Medicaid purchases. (Department of Justice)
That intervention brought federal and state governments directly into the litigation and expanded the financial and regulatory significance of the case.
The Criminal Investigation Is Closed
Civil settlement concludes without criminal findings
Alongside the civil settlement, Abbott said a related criminal investigation has been closed.
That distinction matters because the current agreement resolves civil claims rather than establishing criminal wrongdoing.
The settlement therefore provides financial and legal resolution to the covered civil allegations while leaving Abbott's denial of wrongdoing intact. (Reuters)
The Broader Public-Health Impact
Vulnerable infant populations amplify public health consequences of manufacturing failures
The Abbott case illustrates why infant-formula manufacturing receives unusually close scrutiny.
Infants are especially vulnerable to foodborne pathogens, and powdered formula can create significant public-health consequences when manufacturing controls fail.
A contamination event can trigger a chain reaction: manufacturing concerns → product recalls → plant shutdowns → supply shortages → higher pressure on families and healthcare systems.
The 2022 crisis demonstrated how quickly an industrial manufacturing problem can become a national health and supply issue.
Why Regulatory Compliance Matters
Rigorous quality assurance and transparent reporting are commercially vital
The allegations also show that compliance obligations extend beyond simply producing a product that appears safe.
Manufacturers operating in highly regulated healthcare and nutrition markets have to maintain appropriate manufacturing controls, testing programs, documentation, reporting procedures, quality systems, and regulatory communication.
The Justice Department's allegations centered not just on the conditions at the facilities, but also on what Abbott allegedly told government programs and regulators about compliance. (Department of Justice)
That makes quality assurance and regulatory reporting commercially consequential, particularly when products are purchased using government healthcare funds.
Why This Matters for Healthcare Companies
The settlement is significant for Abbott because it puts a dollar figure on a major legal dispute associated with one of the most disruptive infant-formula events in recent U.S. healthcare history.
The company can now resolve the covered civil claims rather than continuing through potentially lengthy litigation.
At the same time, the case reinforces the reputational sensitivity of businesses serving infants, families and other vulnerable populations.
For healthcare companies, the financial impact of a quality problem can therefore extend well beyond the immediate cost of a recall.
Why This Matters
The $385 million settlement connects three major issues: product safety, government healthcare spending and public trust.
Abbott's products were sold through programs supported by public funds, making the government's allegations relevant not only to food manufacturing but also to the integrity of federally supported healthcare and nutrition programs. (Department of Justice)
The 2022 recall also demonstrated how a manufacturing disruption involving one major supplier can contribute to shortages affecting families across the country. (Reuters)
Although Abbott has not admitted wrongdoing, the settlement closes a substantial civil dispute while leaving important lessons for manufacturers about quality systems, regulatory disclosure and supply-chain resilience.
Looking Ahead
Heightened scrutiny persists for infant nutrition manufacturing oversight
Abbott will continue operating its nutrition business under heightened scrutiny following the history of the Sturgis facility and the 2022 formula crisis.
The settlement provides financial closure for the covered False Claims Act allegations, but broader questions around infant-formula supply resilience, manufacturing oversight and consumer confidence remain important for the industry.
For regulators, the case also reinforces the role of the False Claims Act in pursuing allegations involving products purchased through government-funded programs.
Key Takeaways
- Abbott has agreed to pay $384.999 million plus interest to resolve civil allegations involving infant formula and nutritional products. (Department of Justice)
- The allegations concern Abbott's Sturgis, Michigan, and Casa Grande, Arizona facilities and conduct from 2018 through 2022. (Department of Justice)
- The government alleged that manufacturing conditions increased contamination risks and that Abbott failed to properly test products or notify regulators of positive contamination tests. (Reuters)
- Some products were purchased through USDA and Medicaid-funded programs, including WIC. (Reuters)
- Abbott did not admit wrongdoing, and the settlement contains no finding of liability. (Reuters)
- A related criminal investigation has been closed. (Reuters)
- The dispute followed Abbott's 2022 infant-formula recall and Sturgis plant shutdown, which worsened a nationwide formula shortage. (Reuters)
- The settlement includes approximately $69 million for the whistleblowers who brought the underlying case. (Department of Justice)
What This Means for Healthcare Marketers
For healthcare marketers, this is a strong example of how product quality, regulatory compliance and brand trust are inseparable in healthcare.
When a company serves vulnerable populations, a manufacturing or safety controversy can quickly become a reputational issue involving regulators, providers, government programs, caregivers and the public.
Marketing teams therefore need to monitor more than consumer sentiment. Regulatory actions, recalls, manufacturing disruptions, government contracts, reimbursement programs and litigation can all become early signals of changing market confidence and commercial risk.